Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CVS Expands Formulary Exclusions In 2017, Express Scripts’ Tally Unchanged

Executive Summary

National formulary exclusions continue in 2017, with CVS aggressively expanding its list of “not covered” drugs. Express Scripts currently excludes slightly fewer drugs than last year but may still add to its list.


Related Content

Bristol/Pfizer's Eliquis Better For Preventing Strokes And Bleeding In Large Real-World Trial
CVS 2018 Formulary: Outcomes-Based Contracts In Oncology, Obesity, COPD
Express Scripts Boosts Formulary Exclusions With Focus On Multi-Source Brands
More Pressure On Pradaxa? US Payers May Narrow Coverage Of NOACs
Rise Of The Biosimilar Formulary: CVS Excludes Lantus, Neupogen For 2017
Crestor Generics To Launch After 12-Day Delay
Express Scripts Indication-Based Contracts For Inflammatory Drugs Begin In 2017
Aetna’s Generic Gleevec Approach Combines Specialty Tiering, ‘Fail First’ Strategy
Survey Says: Diabetes The Top Category Targeted For Managing Spend
Express Scripts Tightens Commercial Formulary Control With “Not Covered” List


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts